Filing Details

Accession Number:
0001415889-14-000708
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-28 17:48:33
Reporting Period:
2014-02-26
Filing Date:
2014-02-28
Accepted Time:
2014-02-28 17:48:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1487100 Glenn Baity 11085 Torreyana Road #100
San Diego CA 92121
Vp And Gc No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-26 42,000 $6.17 89,788 No 4 M Direct
Common Stock Disposition 2014-02-26 42,000 $30.28 47,788 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-02-26 42,000 $0.00 42,000 $6.17
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-07-25 No 4 M Direct
Footnotes
  1. Includes 2,273 and 5,515 shares acquired on May 31, 2013 and November 29, 2013, respectively, by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2013.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.62 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  4. 25% of the shares subject to the stock option vested and became exercisable on July 26, 2005. The remaining shares vested in equal monthly installments over the following 3 years.